Filing Analysis
Heron Therapeutics entered into an amendment to its Tax Benefit Preservation Plan, extending the 'Final Expiration Date' from August 14, 2026, to August 14, 2029. This modification is managed through Computershare Trust Company, N.A. as the rights agent.
🚩 Red Flags
- The extension of a 'Tax Benefit Preservation Plan' expiration date can sometimes be used to manage tax liabilities or equity-based compensation structures, though it is not inherently negative without further context.
📋 Key Facts
- Amendment No. 1 to Tax Benefit Preservation Plan entered into on August 13, 2026.
- The amendment extends the 'Final Expiration Date' from August 14, 2026, to August 14, 2029.
- Computershare Trust Company, N.A. serves as the rights agent for the Plan.
Heron Therapeutics, Inc. filed an 8-K to announce its financial results for the three and six months ended June 30, 2026. The filing serves as a formal notice that an earnings press release has been issued.
📋 Key Facts
- Report date: August 10, 2026
- Reporting period: Three and six months ended June 30, 2026
- The filing includes Exhibit 99.1 (Earnings Press Release)
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Heron Therapeutics received a notice from Nasdaq stating the company's stock price fell below the $1.00 minimum requirement for 30 consecutive trading days between May 12, 2026, and June 24, 2026. The company has been granted a 180-day period to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq due to minimum bid price deficiency (Rule 5550(a)(2)).
- Explicit mention of a potential reverse stock split as a method to regain compliance.
- Risk of delisting if the company fails to meet requirements within the extended periods.
📋 Key Facts
- Received written notice from Nasdaq on June 25, 2026.
- Non-compliance period: May 12, 2026, to June 24, 2026.
- Compliance deadline for initial cure: December 22, 2026 (180 days).
- Requirement for compliance: Closing bid price must be at least $1.00 per share for 10 consecutive trading days.
- Potential second 180-day extension is available if the company meets other Nasdaq standards and intends to cure via a reverse stock split.
Heron Therapeutics reported the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. Stockholders approved all six proposals, including the election of directors, the appointment of the accounting firm, and increases to equity incentive and employee stock purchase plans.
🚩 Red Flags
- Significant dilution potential from the approval of 26.56 million additional shares across the Equity Incentive Plan and Employee Stock Purchase Plan.
📋 Key Facts
- Annual Meeting held on June 11, 2026.
- Seven director nominees were elected to serve until the 2027 Annual Meeting.
- Withum Smith+Brown, PC was ratified as the independent registered public accounting firm for fiscal year 2026.
- Approved an increase of 16,560,000 shares for the 2007 Amended and Restated Equity Incentive Plan.
- Approved an increase of 10,000,000 shares for the 1997 Employee Stock Purchase Plan.
- Ratified the adoption of the Tax Benefits Preservation Plan on a nonbinding advisory basis.
- Total outstanding shares entitled to vote as of April 14, 2026, were 188,638,866.
Heron Therapeutics announced that a U.S. District Court ruled on June 1, 2026, that claims in two of its patents (U.S. Patent Nos. 12,115,255 and 12,290,520) covering CINVANTI are invalid. The company intends to appeal this decision to the U.S. Court of Appeals for the Federal Circuit.
🚩 Red Flags
- Loss of patent protection for a core product (CINVANTI) opens the door for generic competition.
- Invalidity ruling is a strong negative signal for the company's intellectual property moat.
📋 Key Facts
- Court decision issued June 1, 2026, declaring U.S. Patent Nos. 12,115,255 and 12,290,520 invalid.
- The patents in question cover the product CINVANTI.
- The litigation stemmed from a Paragraph IV notice received from Slayback Pharma LLC (now owned by Azurity Pharmaceuticals) on December 11, 2023.
- Heron intends to appeal the ruling to the United States Court of Appeals for the Federal Circuit.
- The company states the decision has no impact on prior settlement agreements related to CINVANTI or APONVIE.
Heron Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the three months ended March 31, 2026.
- The report was filed on May 11, 2026.
- Information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- Exhibit 99.1 contains the full Earnings Press Release.
Heron Therapeutics amended employment and retention agreements for its CEO and top executive team, significantly enhancing 'golden parachute' provisions. The updates include the introduction of single-trigger equity acceleration upon a change in control and increased severance payouts.
🚩 Red Flags
- Single-trigger equity acceleration: Equity vests immediately upon a change in control even if the executive remains employed, which is often viewed as shareholder-unfriendly.
- Significant increase in potential cash outflows: CIC severance for the CEO and other executives is set at 200% of salary and bonus, increasing the cost of a potential acquisition.
📋 Key Facts
- CEO Craig Collard's agreement was amended on April 3, 2026, to provide 200% of base salary and bonus if terminated during a Change in Control (CIC) window.
- Retention agreements for the CFO (Ira Duarte), CDO (William Forbes), and COO (Mark Hensley) were also amended to align with the CEO's CIC benefits.
- All four executives now have 'single-trigger' equity acceleration, meaning all outstanding equity vests immediately upon a change in control, regardless of whether they are terminated.
- Non-CIC severance for the CEO includes 100% of base salary and bonus plus 12 months of equity acceleration.
- Restrictive covenants, including non-competition and non-solicitation, were extended to 24 months for all four executives.
- The governing law for all agreements was updated to North Carolina.
Heron Therapeutics, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the three and twelve months ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was furnished as Exhibit 99.1.
- The filing was signed by Ira Duarte, Executive Vice President and Chief Financial Officer, on February 26, 2026.
Heron Therapeutics, Inc. issued an 8-K to announce the release of preliminary financial results for the third quarter and full year ended December 31, 2025.
📋 Key Facts
- The company announced preliminary financial results for the three months ended December 31, 2025.
- The company announced preliminary financial results for the full year 2025.
- The announcement was made via press release on January 9, 2026.
Heron Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the three and nine months ended September 30, 2025. The filing serves as a formal notice that an earnings press release has been issued.
📋 Key Facts
- Report date: November 4, 2025
- Reporting period: Three and nine months ended September 30, 2025
- The filing includes Exhibit 99.1 (Earnings Press Release)
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Heron Therapeutics appointed Thomas Cusack to its Board of Directors and the Nominating and Corporate Governance Committee. His appointment is pursuant to a Cooperation Agreement with Rubric Capital Management LP dated August 8, 2025.
🚩 Red Flags
- Appointment is via a 'Cooperation Agreement' with an investment firm (Rubric Capital Management LP), which often suggests activist investor involvement or pressure from major shareholders.
📋 Key Facts
- Thomas Cusack appointed to the Board on October 27, 2025.
- Term expires at the 2026 Annual Meeting of Stockholders or until successor is elected/qualified.
- Appointment is pursuant to a Cooperation Agreement with Rubric Capital Management LP (dated August 8, 2025).
- Cusack appointed to the Nominating and Corporate Governance Committee.
- Compensation follows standard non-employee director program as disclosed in April 30, 2025 Proxy Statement.
Heron Therapeutics announced that stockholders approved two proposals at a Special Meeting held on October 13, 2025. The approvals allow for the issuance of common stock exceeding 19.99% of outstanding shares in connection with the conversion of senior unsecured promissory notes and Series A Convertible Preferred Stock.
🚩 Red Flags
- Potential significant dilution for existing shareholders due to the conversion of notes and preferred stock.
- The issuance of shares exceeding 19.99% of outstanding common stock is a major dilutive event.
📋 Key Facts
- Special Meeting held on October 13, 2025.
- Proposal 1: Approval to issue common stock via conversion of convertible senior unsecured promissory notes due 2031 (exceeding 19.99% threshold).
- Proposal 2: Approval to issue common stock via automatic conversion of Series A Convertible Preferred Stock (exceeding 19.99% threshold).
- Quorum was met with 95,425,824 shares represented out of 183,314,409 outstanding shares.
- Proposal 1 received 89,632,206 votes 'For'.
- Proposal 2 received 91,534,602 votes 'For'.
Heron Therapeutics entered into a long-term office lease agreement for its new corporate headquarters in Cary, North Carolina. The lease covers approximately 16,837 square feet with an initial term of 111 months.
🚩 Red Flags
- Significant increase in fixed monthly operating expenses ($614k/month base rent plus operating costs).
📋 Key Facts
- Lease dated August 22, 2025, with USEF HCG Fenton LLC.
- Premises located at 25 Fenton Main Street, Cary, NC (approx. 16,837 rentable sq ft).
- Initial term of approximately 111 months.
- One-time option to extend for an additional 84 months.
- Monthly base rent starting at $614,550.50 for the first 12-month term (subject to annual increases).
- Includes a 'right of first refusal' for contiguous vacant space.
Heron Therapeutics has adopted a Tax Benefit Preservation Plan, commonly known as a 'poison pill,' to protect its Net Operating Loss (NOL) assets from being impaired by an ownership change under Section 382 of the Internal Revenue Code. The plan includes the issuance of preferred stock purchase rights triggered if any person acquires 4.99% or more of the company's common stock.
🚩 Red Flags
- Adoption of a 'poison pill' defense mechanism, which often indicates management is bracing for a hostile takeover or activist investor intervention.
- The company explicitly states that recent financing transactions have increased the risk of an ownership change, suggesting potential dilution and capital structure instability.
📋 Key Facts
- Board adopted a Tax Benefit Preservation Plan on August 14, 2025.
- The plan is designed to prevent an 'ownership change' under Section 382 that would limit the use of NOLs.
- A dividend of one preferred stock purchase right will be issued for each share of common stock outstanding as of the close of business on August 15, 2025.
- The rights allow holders to purchase 1/1,000th of a share of Series B Preferred Stock at $7.00 per unit.
- Rights are triggered if an 'Acquiring Person' obtains 4.99% or more of the common stock.
- The plan includes a 'flip-in' provision where holders can acquire shares at a significant discount (2x market value) in the event of a hostile takeover.
Heron Therapeutics has completed a complex series of refinancing transactions involving debt exchanges, new note issuances, and a private placement of equity. The company also entered into a cooperation agreement with Rubric Capital Management to expand its Board of Directors.
🚩 Red Flags
- Significant dilution: The conversion of Series A Preferred Stock results in 5,241,410 common shares, and the note exchange/private placement adds millions of new shares.
- Complex debt restructuring: High volume of interconnected transactions (debt-for-equity swaps and new senior notes) often indicates liquidity pressure.
- Board composition change via 'Cooperation Agreement' suggests potential activist investor involvement or pressure from Rubric Capital Management.
📋 Key Facts
- Closed multiple 'Refinancing Transactions' on August 12, 2025.
- Issued $35.0 million in convertible senior unsecured promissory notes due 2031 at a purchase price of $33.25 million.
- Private placement of 13,225,227 shares of Common Stock and 524,141 shares of Series A Convertible Preferred Stock for ~$27.7 million.
- Series A Preferred Stock has a stated value of $15.00/share and converts to common stock at $1.50 per share (subject to stockholder approval).
- Exchanged $25.0 million of existing senior unsecured convertible notes for 16,666,666 shares of Common Stock.
- Repaid $125.0 million of existing notes in cash as part of the exchange agreement.
- Entered into a Cooperation Agreement with Rubric Capital Management to increase Board size from six to seven and appoint a Rubric-nominated director.
Heron Therapeutics entered into a Framework Agreement with Patheon Austria GmbH & Co KG and Thermo Fisher Scientific Inc. to secure manufacturing and supply for specific products through the end of 2026.
🚩 Red Flags
- Commitment to purchase significant quantities (38,400 kg) creates a fixed supply obligation/liability through 2026.
📋 Key Facts
- Entered into a Framework Agreement on August 6, 2025, with Patheon Austria GmbH & Co KG and Thermo Fisher Scientific Inc.
- Company committed to purchasing 38,400 kg of Products through December 31, 2026.
- Patheon will perform ongoing stability studies and provide warehousing services.
- The agreement terminates certain previous agreements and historical obligations between the parties.
- The arrangement is subject to an existing Amended Manufacturing and Supply Agreement (MSA).
Heron Therapeutics announced a massive restructuring of its debt and capital structure involving multiple complex transactions, including a $150M secured debt amendment, a $150M note exchange (repaying $125M in cash), a $35M convertible note issuance, and a $27.7M private placement.
🚩 Red Flags
- Significant cash outflow: The company must repay $125M in cash to noteholders via the Note Exchange.
- Heavy dilution risk: Multiple issuances of common and preferred stock at prices ($1.50 - $1.80) likely below current market value, plus conversion features.
- Complex debt restructuring: The combination of a large cash repayment and new high-interest secured debt suggests significant liquidity pressure.
- Multiple 8-K items in a single filing (Items 1.01, 2.02, 3.02) indicating a major corporate event.
📋 Key Facts
- Amended Working Capital Facility: Increased to $150M total principal with tranches of $110M (closing), $20M (Dec 2026), and $20M (Sept 2027).
- Note Exchange: Exchanging $25M of existing senior unsecured notes for common stock; repaying the remaining $125M in cash.
- Convertible Note Issuance: Selling $35M in convertible senior unsecured promissory notes at a conversion price of $1.80 per share.
- Private Placement: Selling 13,225,227 shares of common stock and 524,141 shares of Series A Preferred Stock at $1.50 per share for ~$27.7M.
- All major transactions are expected to close on August 12, 2025.
Heron Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on June 12, 2025. The meeting resulted in the election of six directors and the ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 12, 2025.
- Six director nominees (Collard, Dissanaike, Johnson, Kaseta, Morgan, and Waage) were elected to serve until the 2026 Annual Meeting.
- Withum Smith+Brown, PC was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Stockholders approved non-binding advisory compensation (Say-on-Pay) for Named Executive Officers for FY 2024.
- Stockholders approved an annual frequency for future Say-on-Pay advisory votes.
- Quorum was established with 120,003,504 shares represented out of 152,530,696 outstanding shares.
Heron Therapeutics, Inc. filed an 8-K to announce its quarterly earnings results for the three months ended March 31, 2025. The filing serves as a formal announcement of the release of their financial performance data.
📋 Key Facts
- Report date: May 6, 2025
- Reporting period: Three months ended March 31, 2025
- The company issued an Earnings Press Release as Exhibit 99.1
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Heron Therapeutics entered into a settlement agreement with Mylan Pharmaceuticals to resolve ongoing patent litigation in the U.S. District Court for the District of Delaware regarding CINVANTI and APONVIE injectable emulsions.
🚩 Red Flags
- Resolution of patent litigation often involves licensing fees or market restrictions that can impact future revenue streams, though specific terms were not disclosed in this 8-K.
📋 Key Facts
- Settlement reached on May 6, 2025.
- Parties involved: Heron Therapeutics, Inc. and Mylan Pharmaceuticals, Inc.
- Litigation subject: Patent disputes related to CINVANTI (aprepitant) injectable emulsion and APONVIE (aprepitant) injectable emulsion.
- Jurisdiction: U.S. District Court for the District of Delaware.
Heron Therapeutics, Inc. announced the appointment of Mark Hensley as Chief Operating Officer, effective April 28, 2025. The filing details his extensive pharmaceutical leadership background and a comprehensive compensation package including base salary, bonuses, and various equity inducement awards.
🚩 Red Flags
- Significant issuance of new equity (up to 1.9 million shares in options/RSUs) as part of inducement package, which may cause dilution for existing shareholders.
📋 Key Facts
- Mark Hensley appointed as Chief Operating Officer (COO) effective April 28, 2025.
- Hensley previously served as CEO of Veloxis Pharmaceuticals, Inc. from 2021 to 2024.
- Annual base salary is set at $553,000 with a target cash bonus of $276,500 (50% of base).
- Inducement awards include: 500,000 non-statutory stock options, 500,000 restricted stock units (RSUs), and up to 900,000 performance-based stock options (PSO) tied to stock price goals.
- The Inducement Option and PSO have a 10-year term; RSUs vest over four years.
Heron Therapeutics, Inc. filed an 8-K to furnish its earnings press release for the three and twelve months ended December 31, 2024. The filing serves as a formal announcement of the company's quarterly and annual financial results.
📋 Key Facts
- Report date: February 27, 2025
- Reporting period: Three and twelve months ended December 31, 2024
- The filing includes an Earnings Press Release as Exhibit 99.1
- Signed by Ira Duarte, Executive Vice President and Chief Financial Officer
Heron Therapeutics entered into a First Amendment to its Working Capital Facility Agreement with Hercules Capital, Inc. The amendment primarily serves to extend the maturity date of existing debt facilities.
🚩 Red Flags
- Debt maturity linkage: The extension of the working capital facility is tied to the outcome/extension of the 1.5% Convertible Senior Notes due in May 2026, indicating potential refinancing risk or liquidity dependency on those notes.
📋 Key Facts
- Entered into First Amendment to Working Capital Facility Agreement on February 13, 2025.
- The agreement is with Hercules Capital, Inc. (administrative and collateral agent).
- Maturity date extended to the earlier of September 1, 2027, or a date contingent upon the status/extension of the Company's 1.5% Convertible Senior Notes due May 24, 2026.
- The extension is linked to the maturity of the existing Convertible Senior Notes.
Heron Therapeutics, Inc. announced the relocation of its corporate headquarters from San Diego, California to Cary, North Carolina on December 23, 2024.
📋 Key Facts
- Relocation of corporate headquarters from San Diego, CA to Cary, NC.
- Effective date of announcement: December 23, 2024.
- The relocation involves moving the principal executive offices.
Heron Therapeutics announced a significant legal victory in patent litigation against Fresenius Kabi regarding its product CINVANTI. The District Court ruled that Heron's patents are valid and will be infringed by the generic version, effectively delaying generic entry until at least September 2035.
🚩 Red Flags
- The litigation involves the core product CINVANTI; while the outcome was positive for Heron, it highlights the ongoing risk of generic competition in the pharmaceutical sector.
📋 Key Facts
- District Court ruling issued on December 3, 2024, in favor of Heron Therapeutics.
- U.S. Patent Nos. 9,561,229 and 9,974,794 were found valid and infringed by Fresenius Kabi's proposed generic product.
- The patents in question are set to expire in 2035.
- The court ruled that the effective date for any FDA approval of Fresenius Kabi’s ANDA cannot be earlier than September 18, 2035.
- Heron is required to submit a proposed final judgment by December 9, 2024.
Heron Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the three and nine months ended September 30, 2024.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Three and nine months ended September 30, 2024
- The filing includes an Earnings Press Release as Exhibit 99.1
- Filed under Item 2.02 (Results of Operations and Financial Condition)
Heron Therapeutics, Inc. announced the appointment of Michael Kaseta to its Board of Directors on November 4, 2024. The appointment is for a term expiring at the 2025 annual meeting of stockholders.
📋 Key Facts
- Michael Kaseta appointed to the Board of Directors on November 4, 2024.
- Term expires at the Company's 2025 annual meeting of stockholders or until successor is elected/qualified.
- Compensation will follow the standard non-employee director program described in the April 29, 2024 proxy statement.
- Mr. Kaseta will enter into a standard Director Indemnification Agreement.
Heron Therapeutics, Inc. filed an 8-K to furnish its quarterly earnings press release for the three and six months ended June 30, 2024.
📋 Key Facts
- Report date: August 6, 2024
- Reporting period: Three and six months ended June 30, 2024
- The filing is a standard earnings announcement under Item 2.02.
Heron Therapeutics announced that the FDA has acknowledged receipt of a Prior Approval Supplement (PAS) for its product ZYNRELEF. The FDA has set a PDUFA goal date of September 23, 2024.
📋 Key Facts
- FDA acknowledged receipt of Prior Approval Supplement for ZYNRELEF extended-release solution Vial Access Needle.
- PDUFA goal date assigned by the FDA: September 23, 2024.
- The filing is made under Item 7.01 (Regulation FD Disclosure).
Heron Therapeutics held its 2024 Annual Meeting of Stockholders on June 13, 2024, where shareholders approved several key proposals including the election of directors and significant increases to authorized share counts. All six proposals presented at the meeting were successfully passed by the voting stockholders.
🚩 Red Flags
- Significant increase in authorized shares (from 225M to 400M) provides management with substantial capacity for future equity dilution via secondary offerings or warrants.
📋 Key Facts
- Stockholders approved an amendment to increase aggregate authorized shares from 225,000,000 to 400,000,000.
- The 2007 Equity Incentive Plan was amended to increase authorized shares from 39,190,000 to 46,690,000.
- The Employee Stock Purchase Plan (ESPP) was amended to increase authorized shares from 2,225,000 to 3,425,000.
- Six directors were elected to serve until the 2025 Annual Meeting: Craig Collard, Sharmila Dissanaike, M.D., FACS, FCCM, Craig Johnson, Susan Rodriguez, Christian Waage, and Adam Morgan.
- Withum Smith+Brown, PC was ratified as the independent registered public accounting firm for FY2024.
Heron Therapeutics announced the submission of a Prior Approval Supplement to the FDA regarding its ZYNRELEF product. The filing specifically concerns the extended-release solution Vial Access Needle.
📋 Key Facts
- Date of report: May 29, 2024
- Product involved: ZYNRELEF (bupivacaine and meloxicam) extended-release solution
- Action taken: Submitted Prior Approval Supplement to the U.S. FDA
- Specific component: Vial Access Needle for the ZYNRELEF product
Heron Therapeutics, Inc. filed an 8-K to furnish its earnings press release for the three months ended March 31, 2024. The filing serves as a formal announcement of the company's quarterly financial results.
📋 Key Facts
- Report date: May 7, 2024
- Reporting period: Three months ended March 31, 2024
- The filing includes an Earnings Press Release as Exhibit 99.1
- Signed by Ira Duarte, Chief Financial Officer
Heron Therapeutics announced a leadership transition in its finance department. Ira Duarte will assume the role of Principal Accounting Officer on March 29, 2024, replacing Lisa Peraza.
🚩 Red Flags
- None identified; standard executive succession/reassignment.
📋 Key Facts
- Ira Duarte designated as Principal Accounting Officer effective March 29, 2024.
- Lisa Peraza is stepping down from her roles as Chief Accounting Officer and Principal Accounting Officer on the same effective date.
- The transition involves no changes to Ms. Duarte's existing compensation package.
- No related-party transactions were identified in connection with this appointment.
Heron Therapeutics, Inc. filed an 8-K to furnish its earnings press release for the three and twelve months ended December 31, 2023. This is a routine regulatory filing used to disclose quarterly financial results.
📋 Key Facts
- Report date: March 12, 2024
- Reporting period: Three and twelve months ended December 31, 2023
- The filing includes an Earnings Press Release as Exhibit 99.1
- Company is listed on the Nasdaq Capital Market (Ticker: HRTX)
Heron Therapeutics announced that the FDA has approved an indication expansion for its product ZYNRELEF. The approval allows the use of the extended-release solution in soft tissue and orthopedic surgical procedures, specifically including foot and ankle surgeries.
📋 Key Facts
- FDA approved indication expansion for ZYNRELEF (bupivacaine and meloxicam) on January 23, 2024.
- New indications include soft tissue and orthopedic surgical procedures (e.g., foot and ankle).
- The approval applies to procedures where direct exposure to articular cartilage is avoided.
Heron Therapeutics entered into a co-promotion agreement with Crosslink Network, LLC to expand the sales reach of its product ZYNRELEF. The deal involves significant scaling of sales representatives and performance-based equity compensation.
🚩 Red Flags
- Potential dilution through the issuance of up to 1.67M shares based on performance milestones.
- Contingent liabilities: Up to $5M in cash compensation tied to sales growth targets.
📋 Key Facts
- Agreement date: January 5, 2024.
- Product involved: ZYNRELEF (bupivacaine and meloxicam) extended-release solution.
- Crosslink must have at least 325 sales reps by July 1, 2024, and 650+ reps by January 1, 2025.
- Compensation includes fixed-fee per vial based on growth over a baseline period.
- Potential cash compensation up to $5,000,000 if year-over-year sales milestones are met.
- Equity component: Up to 1,666,670 shares of common stock awarded to 'Crosslink Newco' based on performance criteria.
- Term expires December 31, 2028, with automatic one-year renewals unless terminated.
- Change of control triggers acceleration of unvested equity awards during the Initial Period.